LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Her new role is reenvisioning one of KC’s most iconic events for entrepreneurs; how Callie England is shaking up GEW
Callie England misses the life of an entrepreneur, she shared, but her new role with the UMKC Innovation Center — and GEWKC — allows her to stay in the game without being on the field. As of January, the veteran Kansas City startup founder is responsible for managing the branding and marketing initiatives of the…
Sand volleyball tourney for early-career professions works to ‘Spike the Stigma’ on mental health
Joining the workforce is no walk on the beach, said Mark Potts, but give him and his teammates a few hours in the sun and sand on a Saturday afternoon and it could be. “Nobody is on their journey alone,” said Potts, president of the Go Further Foundation, explaining the organization’s purpose and its goal…
Sailes closes $5.1M investment round led by STL firm, with KCRise Fund, Wichita VC
The foundation for Sailes has always been solving difficult problems for sales teams, said Nick Smith; the success of a Series A funding round for the startup will power new tools toward that goal. “Everyone is on this AI hype train, and we’ve been for AI for a while. But it’s not just about using…
EquipmentShare completes another $150M equity raise, building on its Series E funding
COLUMBIA, Missouri — The latest tranche of funding for EquipmentShare puts mid-Missouri’s most earth-moving scaleup close to a half-billion dollars in funding announced over the past six months. EquipmentShare, a Columbia-based equipment and digital solutions provider serving the construction industry, on Wednesday announced it completed an extension of its Series E equity raise, led by funds…